Apr 28, 2020
Viking Therapeutics to Participate in Upcoming Investor Conferences
Feb 26, 2020
Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Feb 19, 2020
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
Jan 06, 2020
Viking Therapeutics to Present at Biotech Showcase 2020
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 05, 2019
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Aug 28, 2019
Viking Therapeutics to Participate in Upcoming Investor Conferences
Jul 25, 2019
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Jul 02, 2019
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
May 02, 2019
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Apr 25, 2019
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Apr 04, 2019
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019
Mar 28, 2019
Viking Therapeutics to Participate in Upcoming Investor Conferences
Mar 13, 2019
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Jan 02, 2019
Viking Therapeutics to Present at Biotech Showcase 2019
Nov 12, 2018
Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018
Nov 07, 2018
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 31, 2018
Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018
Oct 08, 2018
Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)
Oct 04, 2018
Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018